|
1
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin.
66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al: Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): An open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Gefitinib or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rosell R, Carcereny E, Gervais R,
Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, Sanchez JM, et al: Erlotinib versus standard
chemotherapy as first-line treatment for European patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(EURTAC): A multicentre, open-label, randomised phase 3 trial.
Lancet Oncol. 13:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cross DA, Ashton SE, Ghiorghiu S, Eberlein
C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ,
et al: AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated
resistance to EGFR inhibitors in lung cancer. Cancer Discov.
4:1046–1061. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sequist LV, Soria JC, Goldman JW, Wakelee
HA, Gadgeel SM, Varga A, Papadimitrakopoulou V, Solomon BJ, Oxnard
GR, Dziadziuszko R, et al: Rociletinib in EGFR-mutated
non-small-cell lung cancer. N Engl J Med. 372:1700–1709. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Aerts JG, Lievense LA, Hoogsteden HC and
Hegmans JP: Immunotherapy prospects in the treatment of lung cancer
and mesothelioma. Transl Lung Cancer Res. 3:34–45. 2014.PubMed/NCBI
|
|
9
|
Hindson BJ, Ness KD, Masquelier DA,
Belgrader P, Heredia NJ, Makarewicz AJ, Bright IJ, Lucero MY,
Hiddessen AL, Legler TC, et al: High-throughput droplet digital PCR
system for absolute quantitation of DNA copy number. Anal Chem.
83:8604–8610. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xu Q, Zhu Y, Bai Y, Wei X, Zheng X, Mao M
and Zheng G: Detection of epidermal growth factor receptor mutation
in lung cancer by droplet digital polymerase chain reaction. Onco
Targets Ther. 8:1533–1541. 2015.PubMed/NCBI
|
|
11
|
van der Vaart M and Pretorius PJ: The
origin of circulating free DNA. Clin Chem. 53:22152007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schwarzenbach H, Hoon DS and Pantel K:
Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev
Cancer. 11:426–437. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhou Q, Zhang XC, Chen ZH, Yin XL, Yang
JJ, Xu CR, Yan HH, Chen HJ, Su J, Zhong WZ, et al: Relative
abundance of EGFR mutations predicts benefit from gefitinib
treatment for advanced non-small-cell lung cancer. J Clin Oncol.
29:3316–3321. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Karachaliou N, Mayo-de las Casas C,
Queralt C, de Aguirre I, Melloni B, Cardenal F, Garcia-Gomez R,
Massuti B, Sánchez JM, Porta R, et al: Association of EGFR L858R
mutation in circulating free DNA with survival in the EURTAC trial.
JAMA Oncol. 1:149–157. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solidtumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Oxnard GR, Paweletz CP, Kuang Y, Mach SL,
O'Connell A, Messineo MM, Luke JJ, Butaney M, Kirschmeier P,
Jackman DM and Jänne PA: Noninvasive detection of response and
resistance in EGFR-mutant lung cancer using quantitative
next-generation genotyping of cell-free plasma DNA. Clin Cancer
Res. 20:1698–1705. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bai H, Mao L, Wang HS, Zhao J, Yang L, An
TT, Wang X, Duan CJ, Wu NM, Guo ZQ, et al: Epidermal growth factor
receptor mutations in plasma DNA samples predict tumor response in
Chinese patients with stages IIIB to IV non-small-cell lung cancer.
J Clin Oncol. 27:2653–2659. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
He C, Liu M, Zhou C, Zhang J, Ouyang M,
Zhong N and Xu J: Detection of epidermal growth factor receptor
mutations in plasma by mutant-enriched PCR assay for prediction of
the response to gefitinib in patients with non-small-cell lung
cancer. Int J Cancer. 125:2393–2399. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Brevet M, Johnson ML, Azzoli CG and
Ladanyi M: Detection of EGFR mutations in plasma DNA from lung
cancer patients by mass spectrometry genotyping is predictive of
tumor EGFR status and response to EGFR inhibitors. Lung Cancer.
73:96–102. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kimura H, Suminoe M, Kasahara K, Sone T,
Araya T, Tamori S, Koizumi F, Nishio K, Miyamoto K, Fujimura M and
Nakao S: Evaluation of epidermal growth factor receptor mutation
status in serum DNA as a predictor of response to gefitinib
(IRESSA). Br J Cancer. 97:778–784. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang JC, Wu YL, Schuler M, Sebastian M,
Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, et al:
Afatinib versus cisplatin-based chemotherapy for EGFR
mutation-positive lung adenocarcinoma (LUX-lung 3 and LUX-lung 6):
Analysis of overall survival data from two randomised, phase 3
trials. Lancet Oncol. 16:141–151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mok T, Wu YL, Lee JS, Yu CJ, Sriuranpong
V, Sandoval-Tan J, Ladrera G, Thongprasert S, Srimuninnimit V, Liao
M, et al: Detection and dynamic changes of EGFR mutations from
circulating tumor DNA as a predictor of survival outcomes in NSCLC
patients treated with first-line intercalated erlotinib and
chemotherapy. Clin Cancer Res. 21:3196–3203. 2015. View Article : Google Scholar : PubMed/NCBI
|
